IDO1-IN-34

IDO1-IN-34 (Compound 3b) (0.1-100 μM; 48 h) exhibits selective cytotoxicity against a variety of cancer cell lines, with the highest potency against HepG2 cells (GI₅₀ = 0.72 μM). It shows extremely low cytotoxicity against non-cancerous Vero cells, resulting in a selectivity index of 121.58 for HepG2 cells^[1].
IDO1-IN-34 (0.03-0.3 μM; 24 h) dose-dependently reduces kynurenine production in IFN-γ-stimulated SK-OV-3 cells and reverses IDO1-mediated immunosuppression^[1].
IDO1-IN-34 (0.03-0.3 μM; 2 days) restores T cell activation in a dose-dependent manner and increases IL-2 expression in an IDO1-inhibited SK-OV-3/Jurkat T cell co-culture system^[1].
IDO1-IN-34 (0.36-0.72 μM; 24 h) induces apoptosis in HepG2 cells in a dose-dependent manner^[1].
IDO1-IN-34 (0.36-0.72 μM; 48 h) dose-dependently activates the endogenous mitochondrial apoptotic pathway in HepG2 cells, as evidenced by increased levels of cleaved caspase-3, cleaved caspase-9, cleaved PARP-1, and cytochrome c, without activating cleaved caspase-8, a marker of the exogenous apoptotic pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.